AstraZeneca

News

Enhertu shows survival boost in HER2+ solid tumours

AstraZeneca and Daiichi Sankyo's chances of getting approval for Enhertu as a therapy for all HER2-positive tumours – regardless of their location in the body – have just

News

Soliris becomes first drug for paediatric gMG in Europe

AstraZeneca's Soliris has become the first approved treatment in the EU for children and adolescents with generalised myasthenia gravis, a disorder that causes weakness in

News

Jardiance cleared in EU for CKD, challenging Forxiga

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the

News

Pieris wields axe after losing AZ as partner for elarekibep

AstraZeneca has terminated a partnership with Pieris Pharmaceuticals on respiratory drug candidate elarekibep, forcing the latter to slash staff and look into its “strateg

News

Beyfortus cleared by FDA for RSV prevention in infants

Sanofi’s plan to become a dominant player in the respiratory syncytial virus (RSV) market has moved a step closer, with FDA approval of Beyfortus for the prevention of RSV

News

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer –

Enhertu shows survival boost in HER2+ solid tumours

Soliris becomes first drug for paediatric gMG in Europe

Jardiance cleared in EU for CKD, challenging Forxiga

Pieris wields axe after losing AZ as partner for elarekibep

Beyfortus cleared by FDA for RSV prevention in infants

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

AstraZeneca

Editor's Picks